Emerging evidence accumulated over the past several years has uncovered intestinal CD4+ T cells as an essential mediator in modulating intestinal immunity in health and diseases. It has also been increasingly recognized that dietary and microbiota-derived factors play key roles in shaping the intestinal CD4+ T-cell compartment. This review aims to discuss the current understanding on how the intestinal T cell immune responses are disturbed by obesity and metabolic stress. In addition, we review how these changes influence systemic metabolic homeostasis and the T-cell-mediated crosstalk between gut and liver or brain in the progression of obesity and its related diseases. Lastly, we highlight the potential roles of some drugs that target intestinal T cells as a therapeutic treatment for metabolic diseases. A better understanding of the interaction among metabolites, bacterial signals, and T cell immune responses in the gut and their roles in systemic inflammation in metabolic tissues should shed new light on the development of effective treatment of obesity and related disorders.

Keywords: obesity, intestine, T cells, microbiota, dietary signals

INTRODUCTION

Obesity is a key risk factor for many chronic diseases and represents a growing global and serious public health crisis. Recent studies show that individuals with obesity are linked with a great increase in morbidity and mortality from COVID-19 infection (1, 2). Obesity is characterized by low-grade chronic inflammation in key metabolic tissues such as adipose tissues, which control whole-body energy homeostasis (3). The intestinal tract, continuously exposed to dietary factors and foreign antigens, is a critical site of high immune challenge. A complex and highly specialized network of innate and adaptive immune cells is orchestrated to deal with this complex situation, including the largest population of T cells in the body (4). In recent years, emerging evidence has revealed an integral link between the microbial or dietary signals and gut T cell immune responses during obesity development (5–8).

Conventional gut-resident T cells mainly include CD8+ T cells and CD4+ T cells, the latter are generally composed of T-helper 1 (Th1) cells, T-helper 2 (Th2) cells, T-helper 17 (Th17) cells, Follicular helper T (Tfh) cells, and regulatory T (Treg) subsets (4, 9). Th17 cells and Treg cells are the most abundant CD4+ T cells in mucosal tissue. Th17 cells, induced by TGF-β and IL-6 through the master transcription factor RORγt, play a critical role in host defense against fungi and maintenance of intestinal homeostasis through producing IL-17 and/or IL-22 (10, 11). However, aberrant activation of Th17 cells could lead to the pathogenesis of various autoimmune diseases (12). CD25+Foxp3+ Treg cells play a nonredundant role in the maintenance of intestinal homeostasis in a IL-10 and TGF-β-dependent mechanisms (11). Th1 cells, which are a major
source of IFN-γ, are important mediators in the eradication of intracellular pathogens such as viruses and bacteria (13). Th1 cells, characterized by their expression of B cell follicular homing chemokine receptor CXCR5 and co-stimulatory molecules PD-1 (14, 15), help differentiation of germinal center B-cells and production of high-affinity antibody including intestinal IgA (16). In addition to the widely studied conventional CD4+ and CD8+ T cell subsets, the gut is enriched by unconventional T cells, including the γδ T cells, natural killer T (NKT) cells, and mucosal-associated invariant T (MAIT) cells. All these cells are critical regulators in maintaining gut barrier function and immune homeostasis (17, 18). The potential role of these unconventional T cells in intestinal immunity and inflammation has been reviewed elsewhere (19–21). In the current review, we focus on the crosstalk between dietary- and microbiota-derived signals and intestinal T cell immune responses in the regulation of obesity and its related disorders. We also highlight the roles of intestinal T cells in mediating the communication between the gut and other organs in the initiation and progression of metabolic-related diseases. Ultimately, we underline an emerging concept that modulating gut T cells may be an effective approach in treating obesity-induced metabolic diseases.

**INTESTINAL T-CELL ANATOMICAL DISTRIBUTION**

The small and large intestines, which digest and absorb nutrients and water from ingested food, comprise a continuous tube that stretches from the outlet of the stomach to the anus. In the small intestine, the finger-like projections called villi drastically increase the surface area of the small intestine for greater absorption of the digested food. In the colon, villi are absent and the epithelial surface is flat with smaller crypts, which correlates with their function as reabsorbing water from feces and acting as a barrier to the commensal microbiota. Gut homeostasis is maintained by the intestinal epithelial barrier, mucus layer, commensal microbiota as well as the gut immune system (22).

T cells distributed within the small and large intestine are frequently arranged within the gut-associated lymphoid tissue (GALT), which are composed of organized lymphoid tissues and more diffusely scattered lymphocytes (23). The organized lymphoid tissues include mesenteric lymph nodes, Peyers’ patches, isolated lymphoid follicles (ILFs), and the diffusely scattered lymphocytes consists of intraepithelial lymphocytes (IELs) compartment and the lamina propria lymphocytes (LPL) compartment (24, 25). Peyers’ patches occur in the fetal small intestine independent of the intestinal flora (25). The organization of Peyers’ patches is comparable to that of lymph nodes, with large B cell follicles and T cell areas. Peyers’ patches are in close contact with microfold cells (M cells) located in gut epithelium which can capture and transport antigens from the lumen to antigen-presenting cells such as dendritic cells (DCs) in the underlying Peyer’s patches (26). DCs can also form transepithelial dendrites that enable the cells to directly sample luminal antigens (27, 28). These antigen-loaded DCs emigrate through lymphatics to the mesenteric lymph nodes, where they present the captured antigens to T cells (28). The ILFs, with features similar to Peyer’s patches (29), are distributed along the whole intestinal tract, and, unlike Peyer’s patches, their development is triggered by the intestinal flora (30). IELs are in direct contact with the enterocytes and proximity to antigens in the gut lumen, which making them components of the front line of immune defense against invading pathogens (31). There are more IELs in the small intestine compared with the colon (32). IELs are usually CD8+ T cell populations with a significant proportion of γδ TCR (33, 34). By contrast, the majority of the T cells in lamina propria are CD4+ T cells, with only a small population of CD8+ T cells in this location (35). Similar to their distribution within the IELs, lamina propria CD4+ T cells are accumulated at higher levels within the colonic than within the small intestine (11). The vast majority of T cells present in the gut epithelium and lamina propria are antigen-experienced effector/memory phenotypes, making them suitable to quickly deal with both harmless and hazardous stimuli from incoming antigens (35) (Figure 1).

**THE INTESTINAL T CELL IMMUNE RESPONSES INFLUENCED BY OBESITY-ALTERED MICROBIAL AND DIETARY SIGNALS**

The adaptive responses of T cells in the intestine, which are influenced by microbial and dietary factors associated with diet-induced obesity, are critical regulators in systemic inflammation and glucose metabolism.

**Overview of Intestinal T Cells in the Context of Obesity**

High fat diet (HFD) feeding induces changes in intestinal immunity before the onset of systemic low-grade inflammation and insulin resistance (5). It has also been shown that the effects of HFD on intestinal T cells are more confined in the small intestinal lamina propria (SILP) while little or no change is observed in the colon, suggesting that the interaction between the immune system and gut microbiota localized in the SILP is crucial in the development of metabolic disease (5, 36).

Contrary to unaltered Th2 cells in the gut of obese mice, HFD feeding leads to an increase in the proportion of IFN-γ+ Th1 cells and CD8+ T cells in the SILP (5–7). Likewise, T-bet+ Th1 cells are increased in the small intestine and colon of obese patients compared with lean control human subjects (6). IFN-γ−/− mice display improved barrier function compared to wild-type (WT) mice under HFD feeding conditions, implicating that local intestinal IFN-γ production may be one of the critical mediators of intestinal permeability in obesity (6). Consistent with this finding, reduced infiltration of IFN-γ-producing cells in the bowel contributes to the improved gut barrier function of β7-deficient mice under HFD feeding conditions (37).

HFD feeding reduces the proportions and numbers of RORγt+ Treg cells in the SILP (5–7). Consistently, Treg cells are decreased in the small intestine and colon of obese patients compared with lean control human subjects (6). It is
Zhou et al. Intestinal T Cells in Obesity

FIGURE 1 | Anatomical distribution of intestinal T cells. T cells distributed within the small and large intestine are frequently arranged within the gut-associated lymphoid tissue (GALT), which are composed of organized lymphoid tissues including mesenteric lymph nodes, Peyer’s patches, and isolated lymphoid follicles (ILFs) as well as more diffusely scattered lymphocytes including the lamina propria lymphocytes and intraepithelial lymphocytes (IELs). IELs reside within the epithelium layer and are proximity to antigens in the gut lumen, making them components of the front line of immune defense against invading pathogens. There are more IELs in the small intestine compared with the colon. The majority of T cells in lamina propria are CD4+ T cells, with only a small population of CD8+ T cells. Among the CD4+ T cell subsets, Th17 cells and Treg cells are the most abundant cells in the gut, conferring protection against fungi and maintenance of intestinal homeostasis. The organization of Peyer’s patches is comparable to that of lymph nodes, with large B cell follicles and T cell areas. Peyer’s patches are in close contact with microfold cells (M cells) located in gut epithelium which can capture and transport antigens from the lumen to antigen-presenting cells such as dendritic cells (DCs) in the underlying Peyer’s patches. DCs can also form transepithelial dendrites to directly sample luminal antigens and then emigrate to the mesenteric lymph nodes, where they activate naive T cells to induce gut-tropic T cells. The ILFs, with features similar to Peyer’s patches, are distributed along the whole intestinal tract and believed to provide a complementary system for Peyer’s patches.

suggested that the reduction of Porphyromonadaceae, a family within the order Bacteroidales, in the ileum at the onset of HFD feeding could be responsible for the reduction of Th17 cells (5). Co-transfer of Th17 and Treg cells lowers the fasting glucose and insulin levels, improves glucose tolerance and insulin sensitivity in obese Rag1−/− mice, while transfer of Treg cells alone has no effect (7). Consistently, Rag1−/− mice transferred with T cells from RORyt−/− mice showed increased body weight gain, insulin resistance, and hyperinsulinemia compared to those injected with T cells from WT mice even under normal chow diet feeding conditions (5). Induction of IL-22, a major effector cytokine of Th17 cells (38), is impaired in the colon of obese mice during infection (39). In line with this finding, mice deficient in IL-22 receptor are prone to developing metabolic disorders under HFD feeding conditions (1). Accordingly, administration of exogenous IL-22 into genetically obese mice and HFD-fed mice reverses many of the metabolic dysfunctions (1, 40). IL-17 is another critical cytokine produced by Th17. Increasing IL17-expressing cells in the intestine by pretreating mice with dextran sodium sulfate, which increases gut permeability to bacteria and elevates IL17 production, prevents HFD-induced glucose intolerance and insulinopenia (5). In accordance with a decrease in intestinal Th17 cells in mice, T2D patients are more sensitive to intestinal infections with pathogens like Candida guilliermondii compared to healthy controls (41, 42). Notably, the decrease of Th17 cells and IL-17 levels appears to be intestine-specific as elevated IL-17...
levels are observed in peripheral blood, adipose tissues, and livers of obese subjects (43–45), suggesting that Th17 cells may have distinct function in the intestine from that in other tissues. Consistent with this, obesity-induced expansion of Th17 cells in the spleen is associated with inflammatory autoimmune diseases in the brain (46, 47). Taken together, these findings suggest that obesity differentially regulated the immune responses of T cell subsets in the intestine, leading to disturbed gut homeostasis.

Communications Between Gut Microbiota and T Cell Immune Responses

The number and type of bacteria in the gastrointestinal tract vary by region, ranging from about 10^5 per ml in the upper small intestine and up to 10^{12} per ml in the colon (48). It is well established that obesity and T2D are associated with an increase in the ratio of Firmicutes to Bacteroidetes phyla in the gut microbiota (49, 50). The causality of gut microbiota in the development of metabolic diseases is demonstrated in rodents by the finding that microbiota transplantation from obese mice or humans to germ-free recipient mice is sufficient to induce development of metabolic diseases is demonstrated in rodents by the finding that microbiota transplantation from obese mice or humans to germ-free recipient mice is sufficient to induce obesity (51). Obesity and T2D are associated with an increase in the ratio of Firmicutes to Bacteroidetes phyla in the gut microbiota (49, 50). The causality of gut microbiota in the development of metabolic diseases is demonstrated in rodents by the finding that microbiota transplantation from obese mice or humans to germ-free recipient mice is sufficient to induce obesity (51).

Intestinal microbiota plays key roles in mediating T cell function in the gut (52). Th17 cells are absent in the intestine of both germ-free mice and specific pathogen-free animals obtained from Jackson Labs (58). Segmented filamentous bacteria (SFB), which induces serum amyloid A (SAA) that stimulates lamina propria DCs and promotes the development of Th17 cells in the gut (59–61), is much less abundant after 10 and 30 days of HFD feeding (5). Ileum microbiota transplantation experiments further indicate that HFD-induced changes in the gut microbiota may be the direct cause of the decreased Th17 cells in the ileum, which is correlated with increased metabolic dysfunction (5). On the other hand, re-establishment of gut-tropic Th17 cells in the small intestine of obese Rag1-deficient mice results in a significant increase of Bacteroidetes and a decrease of Firmicutes, both changes are associated with leanness (7). Furthermore, a mucin-degrading bacterium Akkermansia muciniphila, which is found to prevent obesity-induced metabolic disorders (62, 63), is also increased after Th17 cell transfer (7). Gut-tropic Treg cells, which express high levels of CCR9, CD103, and killer cell lectin-like receptor G1 (KLRL1), are mostly abundant in the intestine mucosa (64). A significant decrease in the number of Foxp3⁺ Tregs was observed in the colonic but not SILP, of germ-free mice or antibiotic-treated mice (65, 66). These results are consistent with previous observations that germ-free mice have increased proportions of Tregs in small intestine (58), suggesting a differential requirement of microbiota for the induction and maintenance of Treg cells between the small intestine and colon. It is suggested that activation of CD4⁺ T cells in the small intestine is driven mainly by dietary antigens whereas in the colon it is induced by the microbiota (67). Indeed, colonic Treg cells possess unique T-cell receptors (TCRs) different from those used by Treg cells in other organs, further implying an important role for local microbial antigens in shaping the colonic Treg cell population (68).

The Dietary Signals That Influence Intestinal T Cell Immunity

Tfh cells, which are localized in the germinal centers of Peyer's patches and mesenteric lymph nodes, promote class switch and somatic hypermutation in germinal center B cells to produce high-affinity IgA (70). Germ-free mice or mice treated with an antibiotic cocktail show impaired Tfh development within the gut and this microbiota-dependent Tfh development relies on the T-cell intrinsic MyD88 signaling (16). T cell-specific knockout of myeloid differentiation primary response 88 (MyD88) results in abnormal IgA antibody responses and an altered microbial gut community, leading to more severe inflammatory diseases, age-associated obesity, and metabolic disorders (16, 53). On the other hand, oral treatment of germ-free mice with a purified TLR2 agonist alone was capable of significantly increasing germinal center-Tfh abundance within Peyer's patches (16). In summary, these findings raise the possibility that modulating the interplay between microbiota and intestinal T cell immune responses may provide new treating strategies in metabolic diseases.

Bile Acids

Bile acids are cholesterol-derived natural surfactants abundant in the mammalian gut, where they undergo bacteria-mediated transformation to generate a large pool of bioactive molecules that are critical for lipid digestion, antibacterial defense, and glucose metabolism (71, 72). Pharmacologic stimulation of bile acid receptors, which are mainly expressed on immune cells, prevents obesity by decreasing blood glucose levels and increasing insulin sensitivity (73). By contrast, compared with germ-free mice colonized with WT Bacteroides thetaiotaomicron, germ-free mice colonized with the bile salt hydrolase-depleted Bacteroides thetaiotaomicron display reduced body weight gain on a HFD, decreased fat accumulation in blood and liver, and enhanced energy expenditure due to a selective alteration of bile acid pools (74). Lathyr-holic acid, a secondary bile acid metabolite, impedes Th1 activation by decreasing the production of Th1 cytokines IFN-γ and TNF-α (75). Recently, two distinct derivatives of lathyr-holic acid, 3-oxoLCA and isoalloLCA, have been found to impair the differentiation of Th17 cells and increase the differentiation of Treg cells, respectively (76). Combined treatment of mice with these two bile acid metabolites.skews T cells into Treg cell at the expense of Th17 cells in the intestinal lamina propria (76). Since bile acids exist in the gut where abundant Treg and Th17 reside, it would be of great
interest to determine the functional roles of these bile acid derivatives in metabolic diseases.

Retinoic Acid
Retinoic acid, a major metabolite of Vitamin A, is found at higher concentrations in the small intestine and the mesenteric lymph nodes compared with the colon (77). Retinoic acid regulates the intestinal immune homeostasis via generating gut-homing effector T cells and induction of Treg cells (77–79). Retinoic acid is also required to elicit pro-inflammatory CD4+ T cell responses to infection and mucosal vaccination, since blocking retinoic acid receptor signaling results in a cell-autonomous impairment in CD4+ T cell activation (61). Additionally, depletion of vitamin A in obese mice further reduced the proportion of Th17 cells in the small intestine, leading to increased body-weight gain and insulin resistance, while adoptive transfer of in vitro-differentiated gut-tropic Th17 cells to obese mice ameliorates these metabolic disorders (7). These findings reveal a critical role of retinoic acid in T cell function in the regulation of metabolic consequences.

Short-Chain Fatty Acids
Short-chain fatty acids, including acetic, propionic, and butyric acid, are generated in larger quantities through fermentation of sugars, proteins, and soluble fibers (80). Signals from short-chain fatty acids could stimulate metabolite-sensing G protein-coupled receptors (GPR), which are generally expressed on gut immune cells and some gut epithelial cells (81). Among them, GPR43 on Treg cells and GPR109 on DCs appear to be critically important for gut homeostasis. Treg differentiation and its suppressive function are abolished in GPR43-deficient and GPR109-deficient mice (82, 83). Mice fed a HFD with supplement of butyric acid display a significant increase in intestinal Treg generation and energy expenditure (84, 85). However, higher concentrations of butyrate has been found to induce the expression of Th1 master transcription factor T-bet (86), suggesting that butyrate may exert either beneficial or detrimental effects on the mucosal immune system depending on its concentration and immunological milieu.

Dietary Salt
Excessive intake of dietary salt, which is highly contained in the western diet, can lead to hypertension, one of the major complications of obesity (61). Mice fed with a high-salt diet (HSD) for 3 weeks exhibit higher frequencies of lamina propria Th17 cells compared to normal Chow-fed mice via inducing salt-sensing kinase serum glucocorticoid kinase-1 (SGK1) (40). However, these promoting effects are abolished in germ-free mice, indicating a crucial role for intestinal bacteria in mediating the effect of a HSD on Th17 cells (60). Reduced amount of Lactobacillus murinus (L. murinus) may contribute to the increased frequencies of lamina propria Th17 cells within the small intestine and colon (60). In line with this, colonization of germ-free mice with L. murinus could significantly reduce the frequencies of lamina propria Th17 cells induced by SFB (60). HSD also disturbs intestinal homeostasis by attenuating Treg function, either promoting IFN-γ secretion from human Treg cells or decrease luminal levels of Treg-inducing butyrate (43, 50).

Aryl Hydrocarbon Receptor (AhR)
AhR, a widely expressed basic helix-loop-helix transcription factor that is abundantly expressed on murine IELs (87), can be activated by ligands from fruits, nuts, and cruciferous vegetables. AhR activation promotes gene expression of mediators involved in the regulation of gut homeostasis; such mediators include IL-22, anti-microbialidal factors, and increased Th17 cell polarization (81). Alternatively, it is also suggested that AHR regulates both Treg and Th17 cell differentiation in a ligand-specific fashion (88). Lack of AhR signaling in IELs compromises the maintenance of IELs and the control of the microbial load and composition, leading to decreased immune surveillance and increased vulnerability to epithelial damage (87, 89). However, a quantitative trait locus analysis of dietary obesity in C57BL/6 and 129P3/J F2 mice revealed that the AhR gene is one of the seven candidate genes associated with increased body weight (90). Consistently, AhR−/− mice are protected against diet-induced obesity and glucose intolerance (91, 92). These results suggest that T cell-specific, but not systemic, ligation of AhR may provide beneficial effects on defending obesity.

Taken together, although this list of dietary signals on gut T cell performance is not exhaustive, one can postulate that modulating dietary factors may greatly influence intestinal T cell function and consequently gut homeostasis.

INTESTINAL T CELLS UNDER OTHER METABOLIC STRESSES

Aging
The number of IELs both in the small and large intestines are highest in 6-month-old mice and then gradually decreases with age, which may be one of the aging phenomena of the intestinal immune system that increase liability to intestinal infections (93). Th2 immune responses against gastrointestinal nematode parasites are compromised in aging mice, due to inappropriate or insufficient activation of CD4+ T cells in the submucosa (94). T cell-specific ablation of MyD88 impairs Th cell development and IgA production within the gut, leading to age-associated obesity (53). It is suggested that altered gut microbiota and increased lipid absorption are responsible for T cell-mediated regulation of age-associated metabolic disorders (53). Moreover, compared with younger people (<45 years), the small intestinal CD4+ T cells from older human subjects (>65 years) display altered phenotypic and functional profiles including reduced expression of a co-inhibitory molecule, increased spontaneous cell death, and both reduced frequencies and altered functional responses of specific T cell subsets (95). These changes may contribute to altered intestinal homeostasis and loss of protective gut immunity with age.

Food Availability
It has been postulated that early childhood malnutrition confers life-long immunodeficiency with an increased risk for metabolic diseases such as cardiovascular disease and insulin resistance (96, 97). Although the underlying mechanisms remain unclear, it is proposed that defects in the diversity and composition of commensal microbes as well as impaired gut immune function...
in response to malnutrition may contribute to these outcomes (96, 98–100). Consistently, mice weaned onto macromolecule-depleted chow lack peripherally generated Treg cells in the small intestine required for oral tolerance (67). On the other hand, many studies have defined the beneficial effects of caloric restriction on metabolic diseases (101, 102). Intermittent fasting (IF) decreases Th17 but increases Treg cells in the SILP, which, along with enriched beneficial gut bacteria, contribute to the ameliorated experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis diseases (103). However, compared with those of ad libitum-fed juvenile mice, longer time fasting (>36 h) greatly reduced the numbers of IgA+ B cells as well as CD4+ and CD8+ T cells in Peyer's patches, leading to the failure in inducing oral tolerance (104). Consistently, a time-restricted feeding regimen in juvenile mice exacerbated metabolic disorders (105). These findings suggest that factors such as age may affect the outcome of caloric restriction. Nevertheless, it remains to be determined as to how gut T cell immune systems are affected by caloric restriction and malnutrition and to what extent these changes in gut T cells contribute to the physiological outcome in adult mice.

CROSSTALK BETWEEN ANTIGEN-PRESENTING CELLS (APCs) AND T CELLS IN THE INTESTINE

Small intestinal APCs are believed to sample and present commensal bacteria to the gut-associated T cells to maintain immune homeostasis (106). Two major populations of intestinal APCs have been identified based on differential expression of the integrin subunit CD103 and the chemokine receptor CX3CR1 (107). Under steady state, intestinal tolerogenic CD103+ DCs, which are dispersed throughout the lamina propria and can migrate to the draining the mesenteric lymph nodes, are potent generators of Treg cells through their ability to activate TGF-β and metabolize vitamin A into RA, the latter also underlies generators of Treg cells through their ability to activate TGFβ and drive inflammation such as the ability to produce IL-6 and drive Th1 and Th17 responses (110). Intermittent fasting (IF) decreases Th17 but increases Treg cells in the SILP, which, along with enriched beneficial gut bacteria, contribute to the ameliorated experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis diseases (103). However, compared with those of ad libitum-fed juvenile mice, longer time fasting (>36 h) greatly reduced the numbers of IgA+ B cells as well as CD4+ and CD8+ T cells in Peyer's patches, leading to the failure in inducing oral tolerance (104). Consistently, a time-restricted feeding regimen in juvenile mice exacerbated metabolic disorders (105). These findings suggest that factors such as age may affect the outcome of caloric restriction. Nevertheless, it remains to be determined as to how gut T cell immune systems are affected by caloric restriction and malnutrition and to what extent these changes in gut T cells contribute to the physiological outcome in adult mice.

**INTESTINAL T CELL-MEDIATED CROSSTALK BETWEEN GUT AND OTHER TISSUES**

Obesity is associated with an impaired intestinal barrier (49), which causes increased translocation of food antigen, bacterial components, and bacterial metabolites from the gut to various metabolic tissues such as liver and brain, triggering local immune responses (49, 115). Obesity is reported to be associated with higher Parkinson’s disease risk among never smokers (116). It has been proposed that initial α-synuclein aggregation and subsequent Lewy bodies generation in the gut occurred several months before the manifestation of motor symptoms (117). Dysbiosis could lead to an oxidative environment, where oxidized α-synuclein are captured by mucosal DCs and activate intestinal pro-inflammatory Th1 and Th17 cells that play a fundamental role in promoting nigrostriatal neurodegeneration (117, 118). In addition to Parkinson’s disease, growing evidence suggests that obesity is associated with the susceptibility and disease severity of multiple sclerosis (119). In an adoptive-transfer EAE model, the transferred Th17 cells preferentially infiltrate into colonic lamina propria and enter blood circulation via lymphatic vessel. Preventing Th17 cells from entering into the colon significantly attenuates EAE (120). Non-alcoholic fatty liver (NAFLD) is strongly associated with immune turbulence in the mesenteric lymph nodes, with increased ratios of Th1/Th2 cells and Th17/Treg cells (121). These gut-derived memory T cells could migrate to the liver and promote liver inflammation (122–124). Restoration of ratios of the mesenteric lymph node CD4+ T cell subsets markedly alleviates NAFLD progression (121). These studies suggest that intestinal T cell immune responses may play a critical role in mediating inflammatory brain or liver diseases, whereas the detailed mechanisms are remained to be elucidated.

**DRUGS TARGETING INTESTINAL T CELLS IN TREATING OBESITY AND ITS RELATED COMPLICATIONS**

HFD feeding induces an early pro-inflammatory shift in gut immune responses, which contributes to a later-stage systemic low-grade inflammation and obesity-related insulin resistance. Thus, developing treatments that are restricted to the gut...
| Drug     | Disease model                                                                 | Dosage                                      | Intestinal T cell                      | Metabolism                                                                                                 | References |
|----------|-------------------------------------------------------------------------------|---------------------------------------------|----------------------------------------|------------------------------------------------------------------------------------------------------------|------------|
| 5-ASA    | Diet-induced obesity (n = 10–15)                                              | 1,500 or 150 mg/kg/day for 12–14 weeks      | Reduce IFN-γ-producing T cells          | Alleviate Gut and VAT inflammation, improve glucose tolerance, and insulin sensitivity                    | (6)        |
| PACAP    | Subacute ileitis model (Toxoplasma gondii infection, n = 21–26)               | 1.5 mg/kg/day for 6 days from day 3 post-infection (p.i.) until day 8 p.i. | Decrease T cells in ileal and colon     | Alleviate intestinal inflammation                                                                             | (126)      |
| Probiotics (Prohep) | s.c. HCC model (n = 6–8)                                                   | Starting 1 week before or at the same day until 38 days after tumor injection | Downregulate Th17 cells                | Inhibit the liver tumor growth                                                                              | (127)      |
| NX-13    | Adoptive transfer colitis (n = 10) Dextran sodium sulfate colitis (n = 9)     | 0, 1, 10, 20 mg/kg/day for 6–8 weeks DSS group for 7 days | Decrease Th1, Th17 subsets              | Suppress intestinal inflammation                                                                            | (129)      |
| BT-11    | Adoptive transfer colitis (n = 10) DSS colitis (n = 10)                       | 8 mg/kg/day for 6 weeks DSS group for 7 days | Induce Treg cells                      | Alleviate intestinal inflammation                                                                            | (130)      |
| anti-CD3 mAb | Genetic obesity (n = 10)                                                      | 5 µg of anti-CD3 Plus 100 µg of GC for 5 days | Promote Treg generation                | Alleviate inflammation in adipose tissues Reduce hepatic steatosis Reduce AST and fasting plasma glucose level | (134)      |
| Biopsy-proven NASH patients (n = 9) |                                                                        | 0.2, 1.0, 5.0 mg/day for 30 days            |                                                                                      |                                                                                                               | (32)       |

**FIGURE 2** | Intestinal T cell immune responses under steady state. Th17 cells and Treg cells are the most abundant CD4+ T cells in the gut to maintain intestinal homeostasis. Excessive salt intake and AhR ligation both contribute to the increased Th17 cell polarization in the gut, while AhR ligation also required for the induction of Treg cells and maintenance of IELs. Bile acids are cholesterol-derived natural surfactants abundant in the mammalian gut. Lithocholic acid, a secondary metabolite of bile acids, impedes Th1 activation and two distinct derivatives of lithocholic acid, 3-oxo-lithocholic acid and isoval-lithocholic acid, have been found to impair the differentiation of Th17 cells and increase the differentiation of Treg cells, respectively. CD103+ DCs represent the dominant DC population in the murine small intestinal lamina propria (SILP). CD103+ DCs induce the gut-homing receptors CCR chemokine receptor (CCR9) and α4β7 on responding T cells and Treg cell differentiation, both of which are dependent on signaling events initiated by the vitamin A metabolite, retinoic acid (RA). Short-chain fatty acids (SCFAs) could also induce Treg polarization directly through a receptor GPR43 on T cells or indirectly through a receptor GPR109 on CD103+ DCs. Segmented filamentous bacteria (SFB) induce serum amyloid A (SAA) production from gut epithelial cells and stimulates CX3CR1+ DCs to promote Th17 cell development in the gut, the latter process could also be induced by commensal origin-derived ATP stimulation. Clostridium strains provide an environment rich in TGF-β that induces IL-10-producing colonic Treg Cells. Bacteroides fragilis (B. fragilis) promotes the differentiation and function Treg via its immunomodulatory molecule polysaccharide A (PSA), where Toll-like receptor 2 (TLR2) signaling is required. TLR2 ligand could also stimulate Tfh development in the germinal center to facilitate IgA production by B cells. Taken together, IL-17 and IL-22 produced by Th17, IL-10 and TGF-β produced by Treg cells, and IgA in the gut lumen constitue an immune barrier in maintaining gut homeostasis in steady state.
Zhou et al. Intestinal T Cells in Obesity

inflammation could avoid broad systemic deleterious effects and be an effective approach for metabolic disease (6).

5-aminosalicylic acid (5-ASA), first-line therapy for inflammatory bowel disease (IBD) in humans (125), contributes to improved systemic metabolic parameters in mice during HFD feeding through changes in intestinal barrier function, fat inflammation, and oral tolerance to gut luminal antigen (6). Specifically, 5-ASA reduces IFN-γ-producing Th1 and CD8+ T cells while promotes Treg cell accumulation in the intestine, leading to alleviated gut and even visceral adipose tissue inflammation in mice (6). Pituitary adenylyl cyclase-activating polypeptide (PACAP), a neuropeptide well-known for its functions in inhibiting inflammation, decreases the number of apoptotic epithelial T cells in the ileal and colon of mice (126). In addition, a novel probiotic mixture, Prohep, inhibits liver tumor growth in mice by downregulating Th17 cells in the small intestine which could otherwise contribute to liver tumor growth after migrating to the liver via the cardiovascular system (127). NX-13, an orally active, gut-restricted novel drug (128), decreases the differentiation of Th1 and Th17 subsets in an NLRX1-dependent manner in vitro, which contributes to alleviated disease severity of mouse IBD models (129). Besides, BT-11, an investigational new drug for IBD, has been found to alleviate IBD by inducing Treg cells in the mouse colonic lamina propria through controlling glucose flux and enhancing IL2/STAT5 signaling axis (130, 131). It has been shown that oral anti-CD3 mAb is absorbed in gut-associated lymphoid tissue and stimulates CD4+CD25+LAP+ Tregs to suppress autoimmune diseases (132), like autoimmune diabetes in NOD mice (133). Oral anti-CD3 plus β-glucosylceramide (an NKT cell target antigen) treatment promotes Treg cell generation in mesenteric lymph nodes and bowel and alleviates inflammation in adipose tissue and improves hepatic steatosis in ob/ob mice (134). Accordingly, non-alcoholic steatohepatitis patients with oral OKT3 (anti-CD3 antibody) shows increased Treg cell proportions and reduced AST and fasting plasma glucose levels and alleviated insulin resistance (32). Taken together, these studies suggest that targeting gut T cells holds huge potential in treating obesity and its associated diseases (Table 1).

CONCLUSIONS AND PERSPECTIVES

In this review, we discuss the connection between intestinal local environments influenced by diets, specific microbes, metabolites, and gut T cell immune responses. We also highlight how the connection contributes to metabolic health and disease
We conclude that the imbalance of intestinal flora and modified APCs induced by HFD feeding directly or indirectly contribute to the dysregulation of T cell responses in the intestine, with increased Th1 and CD8^+ T cells as well as decreased Th17 and Treg cells. These T cell immune turbulence leads to intestinal inflammation and impaired gut barrier function, which contributes to subsequent obesity and insulin resistance. Besides, dysbiosis caused by defects in Th17 development and IgA production also critically involved in the HFD- and age-associated obesity (Figure 3).

While accumulating evidence strongly suggests that intestinal T cells are potential therapeutic targets of metabolic diseases, many questions remain to be answered. It has been shown that, compared with younger people, the function of small intestinal CD4^+ T cells in older people is reduced, concurrently with increased spontaneous cell death (95). However, it is currently unknown whether these changes contribute to aging-associated alterations in intestinal and metabolic homeostasis. Besides, cold exposure markedly shifts the composition of the gut microbiota, which contributes to thermogenesis and enhanced insulin sensitivity (135). Since gut microbiota is tightly associated with T cell immune responses (57) and thermogenesis is thought to boost mucosal immunity (136), it is worth determining whether intestinal T cells are involved in cold-induced thermogenesis. In addition, the ecology of gut microbiota and the composition of the intestine immune system vary according to the intestinal segments (48, 137). Therefore, the contributions of the interplay between microbiota and immune system in the gut to metabolic diseases may be intestinal segment-dependent and thus location distinct. What is more, controlling dysbiosis of gut microbiota by adaptive immunity is critically involved in the improvement of metabolic features, suggesting that vaccination may be considered as a possible therapeutic approach for T2D (36). Finally, a better understanding of the key cellular components of the intestinal T cell immune responses and their regulatory network, and how they control systemic metabolic homeostasis will allow researchers to design improved targeted therapies to treat intestinal and metabolic disorders.

The gut microbiota is tightly associated with T cell immune responses (57) and thermogenesis is thought to boost mucosal immunity (136), it is worth determining whether intestinal T cells are involved in cold-induced thermogenesis. In addition, the ecology of gut microbiota and the composition of the intestine immune system vary according to the intestinal segments (48, 137). Therefore, the contributions of the interplay between microbiota and immune system in the gut to metabolic diseases may be intestinal segment-dependent and thus location distinct. What is more, controlling dysbiosis of gut microbiota by adaptive immunity is critically involved in the improvement of metabolic features, suggesting that vaccination may be considered as a possible therapeutic approach for T2D (36). Finally, a better understanding of the key cellular components of the intestinal T cell immune responses and their regulatory network, and how they control systemic metabolic homeostasis will allow researchers to design improved targeted therapies to treat intestinal and metabolic disorders.

**AUTHOR CONTRIBUTIONS**

HZ organized and wrote the draft. LW participated in the draft writing. FL revised the whole manuscript and offered constructive comments. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by grants from the National Nature Science Foundation of China (Grant Nos. 81730022 and 81606071), and grants from the National Key R&D Program of China (2018YFC2000100 and 2019YFA0801903), and grants from the Nature Science Foundation of Hunan Province, China (Grant No. 2019JJ50867).

**REFERENCES**

1. Tartof S, Qian L, Hong V, Wei R, Nadjaﬁ R, Fischer H, et al. Obesity and mortality among patients diagnosed with COVID-19: results from an integrated Health Care Organization. Ann Int Med. (2020) 173:773–81. doi: 10.7326/M20-3742

2. Popkin BM, Du S, Green WD, Beck MA, Algath T, Herbst CH, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. (2020) 21:e13128. doi: 10.1111/obr.13128

3. Zhou H, Liu F. Regulation, communication, and functional roles of adipose tissue-resident CD4^+ T cells in the control of metabolic homeostasis. Front Immunol. (2018) 9:1961. doi: 10.3389/fimmu.2018.01961

4. Field CS, Baixauli F, Kyle RL, Puleston DJ, Cameron AM, Sanin DE, et al. Mitochondrial integrity regulated by lipid metabolism is a cell-intrinsic checkpoint for treg suppressive function. Cell Metab. (2020) 31:422–37.e5. doi: 10.1016/j.cmet.2019.11.021

5. Gasioudou L, Pomie C, Klopp P, Waget A, Charpentier J, Aloulou M, et al. The gut microbiota regulates intestinal CD4^+ T cells expressing Rorgammat and controls metabolic disease. Cell Metab. (2015) 22:100–12. doi: 10.1016/j.cmet.2015.06.001

6. Luck H, Tsai S, Chung J, Clemente-Casares X, Ghazarian M, Revelo XS, et al. Regulation of obesity-related insulin resistance with gut anti-inflammatory agents. Cell Metab. (2015) 21:527–42. doi: 10.1016/j.cmet.2015.03.001

7. Hong CP, Park A, Yang BG, Yun CH, Kwak MJ, Lee GW, et al. Gut-specific delivery of T-helper 17 cells reduces obesity and insulin resistance in mice. Gastroenterology. (2017) 152:1998–2010. doi: 10.1053/j.gastro.2017.02.016

8. Cerboni S, Jeremiah N, Gentili M, Gehrmann U, Conrad C, Stolzenberg MC, et al. Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes. J Exp Med. (2017) 214:1769–85. doi: 10.1084/jem.20161674

9. Bollrath J, Powrie FM. Controlling the frontier: regulatory T-cells and intestinal homeostasis. Semin Immunol. (2013) 25:352–7. doi: 10.1016/j.smim.2013.09.002

10. Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell. (2010) 140:845–58. doi: 10.1016/j.cell.2010.02.021

11. Shale M, Schiering C, Powrie F. CD4^+ T-cell subsets in intestinal inflammation. Immunol Rev. (2013) 252:164–82. doi: 10.1111/imr.12039

12. Zhou H, Wang Y, Lian Q, Yang B, Ma Y, Wu X, et al. Differential IL-10 production by DCs determines the distinct adjuvant effects of LPS and PTX in EAE induction. Eur J Immunol. (2014) 44:1352–62. doi: 10.1002/eji.201343744

13. Lighvani AA, Frucht DM, Jankovic D, Yamane H, Aliberti J, Hissong BD, et al. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci USA. (2001) 98:15137–42. doi: 10.1073/pnas.26157095

14. Johnston RJ, Poholek AC, DiToro D, Yusuf I, Eto D, Barnett B, et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science. (2009) 323:1006–10. doi: 10.1126/science.1175870

15. He L, Gu W, Wang M, Chang X, Sun X, Zhang Y, et al. Extracellular matrix protein 1 promotes follicular helper T cell differentiation and antibody production. Proc Natl Acad Sci USA. (2018) 115:8621–6. doi: 10.1073/pnas.1801196115

16. Kubinak JL, Petersen C, Stephens WZ, Soto R, Bake E, O’Connell RM, et al. MyD88 signaling in T cells directs IgA-mediated control of the microbiota to promote health. Cell Host Microbe. (2015) 17:153–63. doi: 10.1016/j.chom.2014.12.009

17. Toubal A, Kief B, Beaudoin L, Cagninacci L, Rhimi M, Fruchet B, et al. Myeloid-associated invariant T cells promote inflammation and intestinal dysbiosis leading to metabolic dysfunction during obesity. Nature Communications. (2020) 11:3755. doi: 10.1038/s41467-020-17307-0
Lefrancois L, Puddington L. Intestinal and pulmonary mucosal T cells: phenotypic complexity of intraepithelial lymphocyte s of the gut mucosa. *Nature* (2013) 500:541–6. doi: 10.1038/nature12506

Wu J, Chen YJ, Dobbs N, Sakai T, Liu J, Mijer JJ, et al. STING-mediated disruption of canine homeostasis chronically activates ER stress and primes T cell death. *J Exp Med.* (2019) 216:867–83. doi: 10.1084/jem.20182192

Wu C, Yosef N, Thalhammer T, Zhu C, Xiao S, Kishi Y, et al. Induction of pathogenic TH17 cells by inducible salting-sensing kinase SGK1. *Nature.* (2013) 498:513–7. doi: 10.1038/nature12198

Khovdunhunkット S, Suwantuntula T, Thaweboon S, Mitirattanakul S, Chomkhakkiu U, Khovidhunkット W. Xerostomia, hyposalivation, and oral microbiota in type 2 diabetic patients: a preliminary study. *J Med Assoc Thai.* (2009) 92:1220–8.

Rodrigues C, Rodrigues M, Henriques M. Candida sp. infections in patients with diabetes mellitus. *J Clin Med.* (2019) 8:76. doi: 10.3390/jcm8010076

Hernandez A, Kitz A, Wu C, Lowlther D, Rodriguez D, Vudattu N, et al. Sodium chloride inhibits the suppressive function of FOXP3+ regulatory T cells. *J Clin Investig.* (2015) 125:4212–22. doi: 10.1172/JCI81151

Forchielli ML, Walker WA. The role of gut-associated lymphoid tissues and mucosal defence. *Br J Nutr.* (2003) 9(Suppl. 1):S41–8. doi: 10.1079/BIN20041356

Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. *Nat Rev Immunol.* (2005) 5:331–41. doi: 10.1038/nri1507

Reboldi A, Cyster J. Peyer’s patches: organizing B-cell responses at the mucosal interface. *Nat Rev Drug Discov.* (2013) 12:4280. doi: 10.1038/immunol.2013.0280

Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eideneschken C, et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. *Nature.* (2014) 514:237–41. doi: 10.1038/nature13564

Richness of human gut microbiome correlates with metabolic markers. *Science.* (2005) 307:254–8. doi: 10.1126/science.1102901

Winer S, Palser G, Chan Y, Tsui H, Engleman E, Winer D, et al. Obesity predisposes to TH17 bias. *Eur J Immunol.* (2009) 39:2629–35. doi: 10.1007/ej.200838893

Cantarel BL, Labarre P, Ch彩神on C, Maarek T, Salzet M, et al. KEGG as a reference resource for basic biological knowledge. *Nucleic Acids Res.* (2010) 38:D144–D50.
60. Wilck N, Matus M, Kearney S, Olesen S, Forslund K, Bartolomaeus H, et al. Salt-responsive gut commensal modulates T17 axis and disease. *Nature*. (2017) 551:585–9. doi: 10.1038/nature24628

61. Siracusa F, Schallenberg N, Villalblanca E, Huber S, Gagliani N. Dietary habits and intestinal immunity: from food intake to CD4 T cells. *Front Immunol*. (2018) 9:3177. doi: 10.3389/fimmu.2018.03177

62. Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. *Nat Med*. (2017) 23:107–13. doi: 10.1038/nm.4236

63. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. *Proc Natl Acad Sci USA*. (2013) 110:9696–71. doi: 10.1073/pnas.1219451110

64. Feuerer M, Hill JA, Kretschmer A, von Boehmer H, Mathis D, Benoist C. Genomic definition of multiple ex vivo regulatory T cell subphenotypes. *Proc Natl Acad Sci USA*. (2010) 107:5919–24. doi: 10.1073/pnas.1002061107

65. Nutsch K, Chai J, Ai T, Russler-Germain E, Feehley T, Nagler C, et al. Rapid and efficient generation of regulatory T cells to commensal antigens in the periphery. *Cell reports*. (2016) 17:206–20. doi: 10.1016/j.celrep.2016.08.092

66. Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, et al. Bile acid metabolites with the ability to generate gut-tropic T cells. *Mucosal Immunol*. (2011) 4:531–9. doi: 10.1038/mi.2010.434

67. Kim K, Hong S, Han D, Yi J, Jung J, Yang B, et al. Dietary antigens limit intestinal inflammation. *Science*. (2016) 351:858–63. doi: 10.1126/science.aac5560

68. Lathrop SK, Bloom SM, Rao SM, Nutsch K, Lio CW, Santacruz N, et al. Peripheral education of the immune system by colonic commensal microbiota. *Nature*. (2011) 478:250–4. doi: 10.1038/nature10434

69. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. *Proc Natl Acad Sci USA*. (2010) 107:12204–9. doi: 10.1073/pnas.0909122107

70. Crotty S. Follicular helper CD4 T cells (TFH). *Annu Rev Immunol*. (2012) 30:427–63. doi: 10.1146/annurev-immunol-031210-101400

71. Hofmann AF, Hagey LR. Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. *J Lipid Res*. (2014) 55:1533–95. doi: 10.1194/jlr.R049437

72. Duboc H, Rajca S, Rainteau D, Benarous D, Maubert MA, Quervain E, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. *Gut*. (2013) 62:531–9. doi: 10.1136/gutjnl-2012-302578

73. Ma H, Patti ME. Bile acids, obesity, and the metabolic syndrome. *Best Pract Res Clin Gastroenterol*. (2018) 7:e37182. doi: 10.7554/eLife.37182

74. Yao L, Seaton S, Ndousse-Fetter S, Adhikari A, DiBenedetto N, Mina A, et al. Bile acid metabolites improve insulin sensitivity and increases energy expenditure in mice. *Diabetes*. (2009) 58:1509–17. doi: 10.2337/db08-1637

75. Arpaia N, Campbell C, Fan X, Diky S, van der Weeken J, deRoos P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature*. (2013) 504:451–5. doi: 10.1038/nature12726

76. Hang S, Paik D, Yao L, Kim E, Padia R, Shi H, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. *Immunity*. (2014) 40:128–39. doi: 10.1016/j.immuni.2013.12.007

77. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. *Diabetes*. (2011) 60:1979–88. doi: 10.2337/db11-0392

78. Smith P, Howitt M, Panikov N, Michaud M, Gallini C, Bohlooly-Y M, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science*. (2013) 341:569–73. doi: 10.1126/science.1241165

79. Singh N, Gurav A, Sivapragasam S, Brady E, Padia R, Shi H, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. *Immunity*. (2014) 40:128–39. doi: 10.1016/j.immuni.2013.12.007

80. Zhou et al. Intestinal T Cells in Obesity
partitioning of intestinal microbiota. *Gastroenterology.* (2014) 147:1055–63 e8. doi: 10.1053/j.gastro.2014.07.020

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.